

Vectibix (panitumumab)

Override	Approval Duration
Prior Authorization	1 year

Medication
Vectibix (panitumumab)

APPROVAL CRITERIA:

Requests for Vectibix (panitumumab) may be approved if the following criteria are met:

- I. Individual has a diagnosis of stage IV colon, rectal, colorectal, appendiceal, or anal adenocarcinoma (Label, NCCN 2A); **AND**
- II. Panitumumab is used as a single agent or as part of combination therapy; **AND**
- III. Extended RAS gene mutation testing with an FDA approved test is confirmed and the tumor is determined to be RAS wild-type*; **AND**
- IV. Panitumumab used in a single line of therapy; **AND**
- V. Panitumumab is not used in combination with anti-VEGF agents (bevacizumab, ziv-aflibercept, or ramucirumab) (NCCN 2A); **AND**
- VI. Individual has not received prior treatment** with cetuximab (NCCN 2A)

***Note:** RAS wild-type means that the KRAS and NRAS genes are normal or lacking mutations.

****Note:** A course of cetuximab discontinued because of adverse reaction, not progressive disease, is not considered prior treatment.

Requests for Vectibix (panitumumab) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. Treatment of RAS-mutant metastatic colorectal cancer, small bowel or anal adenocarcinoma, (that is, when an FDA approved test has confirmed the presence of genetic mutations in any of the RAS genes) **or** when RAS mutation status is unknown; **OR**
- III. In combination with other monoclonal antibodies or anti-VEGF agents; **OR**
- IV. Treatment of penile cancer; **OR**
- V. Treatment of squamous cell anal carcinoma.

Note:

Vectibix (panitumumab) has a black box warning for dermatologic toxicity. Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC grade 3 and higher) in 15% of patients receiving Vectibix monotherapy.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 16, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 16, 2019.
 - a. Anal Carcinoma. V1.2020. Revised November 19, 2020.
 - b. Colon Cancer. V2.2020. Revised March 3, 2020.
 - c. Small Bowel Adenocarcinoma. V 1.2020. Revised July 30, 2019.
 - d. Rectal Cancer. V2.2020. Revised March 3, 2020.